Gallen International Consensus Panel on the Treatment of Early Breast Cancer recommended adjuvant chemotherapy, particularly with anthracyclines, for most women with early breast cancer, regardless of nodal, menopausal or hormonal receptor status (Eifel et al, 2001; Goldhirsch et al, 2001); as a consequence anthracycline-containing regimens are used as adjuvant therapy in the majority of patients with early breast cancer. Here, NR4A1 is linked to breast cancer.